Example: Heart Attack

Clinical Trials on Glabellar Crease

Total 10000 results

NCT04745975

Recruiting

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Triple Negative Breast Cancer
NCT04676997

Recruiting

Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer
NCT03913234

Recruiting

Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients

Metastatic Breast Cancer | HER2-positive Breast Cancer | Postmenopausal
NCT03876886

Recruiting

The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency

Triple Negative Breast Cancer
NCT03671044

Recruiting

A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

Triple Negative Breast Cancer
NCT02615457

Recruiting

Huaier Granule in Treating Women With Triple Negative Breast Cancer

Triple Negative Breast Cancer
NCT02341911

Recruiting

Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC) (TNBC)

Breast Cancer
NCT06618014

Active, not recruiting

Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP) (NeoTOP)

Breast Cancer | Triple Negative Breast Cancer
NCT03609047

Active, not recruiting

Adjuvant Palbociclib in Elderly Patients With Breast Cancer (Appalaches)

Breast Cancer Stage II | Breast Cancer Stage III
NCT05645380

Active, not recruiting

Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC (NeoTRACT)

Breast Cancer | Triple Negative Breast Cancer
NCT04877821

Completed

The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC (NeoSACT)

Triple Negative Breast Cancer
NCT03270072

Active, not recruiting

The Differential Impact of Proton Beam Irradiation Versus Conventional Radiation on Organs-at-risk in Stage II-III Breast Cancer Patients

Breast Cancer Stage II | Breast Cancer Stage III
NCT03586297

Completed

Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer

Triple Negative Breast Cancer
NCT04068623

Active, not recruiting

Correlation Between TILs and Blood Cell Counts in Triple Negative Breast Cancer Patients (PERCEPTION)

Triple Negative Breast Cancer
NCT05333874

Active, not recruiting

CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage

Breast Cancer, Early-Onset
NCT04758780

Completed

Imaging Performance Assessment of 89Zi-girentuximab (89Zr-TLX250) PET in Metastatic Triple Negative Breast Cancer (OPALESCENCE)

Triple Negative Breast Cancer
NCT06001762

Active, not recruiting

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Breast Cancer | Early-stage Breast Cancer | High Risk Breast Carcinoma
NCT03542175

Completed

A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy

Breast Cancer
NCT04438681

Active, not recruiting

Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Breast Cancer Patients (INSTIGO)

Triple Negative Breast Cancer
NCT02826434

Active, not recruiting

Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer

Breast Cancer
NCT07185334

Active, not recruiting

Single-Stage Prepectoral Placement of Textured Implants Using a Polyester Mesh Endoprostheses With Fluoropolymer Coating in Patients With Breast Cancer (FluoropolyMesh)

Breast Cancer | Reconstruction Breast Surgery | Breast Reconstruction | Coated Materials | MASH With Fibrosis
NCT05300958

Terminated

Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer

Triple Negative Breast Cancer
NCT02455141

Active, not recruiting

Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer (TCTN)

Breast Neoplasm
NCT02788981

Active, not recruiting

Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer

Breast Cancer
NCT04849364

Terminated

Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE)

Breast Cancer | Triple Negative Breast Cancer
NCT03562637

Active, not recruiting

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

Triple Negative Breast Cancer
NCT01982448

Completed

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

Triple Negative Breast Cancer
NCT05113966

Terminated

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Triple Negative Breast Cancer
NCT04807192

Active, not recruiting

CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer
NCT05837533

Completed

Multicenter Study to Evaluate a Systematized Communication Model for Breast Cancer Patients

Communication | Breast Cancer Stage IV | Breast Cancer Metastatic
NCT03800836

Completed

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Breast Cancer
NCT04464174

Completed

Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer (PATHFINDER)

Triple Negative Breast Cancer
NCT05134194

Terminated

A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer
NCT03281954

Active, not recruiting

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

Triple Negative Breast Cancer
NCT03337724

Completed

A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (IPATunity130)

Breast Cancer
NCT04690855

Terminated

A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer (TARA)

Breast Cancer | Triple Negative Breast Cancer
NCT03358017

Completed

Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer (YAPPETIZER)

Triple Negative Breast Cancer
NCT04720664

Terminated

Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer (OASIS)

Breast Cancer | Metastatic Breast Cancer | Hormone Receptor Positive Breast Carcinoma
NCT03567720

Active, not recruiting

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

Triple Negative Breast Cancer
NCT02322814

Terminated

A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

Breast Cancer
NCT01036087

Completed

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Breast Cancer
NCT04368468

Completed

Modifications of Immune Microenvironment Induced by Neoadjuvant Chemotherapy in Triple-negative BC (MIMOSA)

Triple Negative Breast Cancer
NCT04268693

Withdrawn

Bisphenol and Phthalate Exposures in Triple Negative Breast Cancer (EDC-TNBC)

Triple Negative Breast Cancer
NCT05576545

Completed

Develop and Evaluate the Effectiveness of a Self-Care Smartphone Application on the Self-Efficacy, and Resilience Among Newly Diagnosed Breast Cancer Patients Undergoing Treatment

Breast Cancer | Breast Neoplasm | Resilience | Self-efficacy | Breast Malignant Tumor
NCT04297267

Active, not recruiting

A Study to Evaluate Gemcitabine Plus Cisplatin in the Treatment of TNBC Patients Following Neoadjuvant Chemotherapy (nonpCR GP)

Triple Negative Breast Cancer
NCT02425891

Completed

A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

Triple Negative Breast Cancer
NCT02419807

Completed

Comparison of Use of Indocyanine Green and 99mTc-labeled Radiotracer for Axillary Lymphatic Mapping in Patients With Breast Cancer

Stage I Breast Cancer | Stage II Breast Cancer
NCT04105582

Completed

Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells

Breast Cancer | Triple Negative Breast Cancer
NCT02574455

Completed

Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) (ASCENT)

Breast Cancer
NCT02513472

Completed

Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) (ENHANCE-1)

Breast Neoplasm

Clinical Trials on Glabellar Crease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations